Results of a prospective study of patients with breast or prostate cancer demonstrate the impact of taxane-based chemotherapy on quality of life.
Breast cancer survivors who received taxane-based chemotherapy for their disease are at increased risk for falls due to CIPN and treatment-associated effects on balance and gait.
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
Sign Up for Free e-newsletters
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- FDA Approves HPV Vaccine for People Through Age 45
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Strength and Hope for Women in the Mist of Cancer
- Prospective Study Measures Cognitive, Treatment Effects in Older Breast Cancer Survivors
- Immune Checkpoint Inhibitor Therapy May Affect Thyroid Function
- Hypofractionated Radiotherapy After Conservative Surgery May Increase Low-intermediate Grade Late Fibrosis in Breast Cancer Patients
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|